Rachael Natrajan

High-resolution deletion mapping of 15q13.2-q21.1 in transitional cell carcinoma of the bladder.

Prognostic classification of relapsing favorable histology Wilms tumor using cDNA microarray expression profiling and support vector machines.

Array CGH using whole genome amplification of fresh-frozen and formalin-fixed, paraffin-embedded tumor DNA.

Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization.

Blastemal expression of type I insulin-like growth factor receptor in Wilms' tumors is driven by increased copy number and correlates with relapse.

Amplification and overexpression of CACNA1E correlates with relapse in favorable histology Wilms' tumors.

Delineation of a 1Mb breakpoint region at 1p13 in Wilms tumors by fine-tiling oligonucleotide array CGH.

Getting it right: designing microarray (and not 'microawry') comparative genomic hybridization studies for cancer research.

Chromogenic and fluorescent in situ hybridization in breast cancer.

Multifaceted dysregulation of the epidermal growth factor receptor pathway in clear cell sarcoma of the kidney.

Resistance to therapy caused by intragenic deletion in BRCA2.

Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines.

ESR1 gene amplification in breast cancer: a common phenomenon?

Loss of 16q in high grade breast cancer is associated with estrogen receptor status: Evidence for progression in tumors with a luminal phenotype?

PPM1D is a potential therapeutic target in ovarian clear cell carcinomas.

Tiling path genomic profiling of grade 3 invasive ductal breast cancers.

CD44 is overexpressed in basal-like breast cancers but is not a driver of 11p13 amplification.

Integrated functional, gene expression and genomic analysis for the identification of cancer targets.

Mixed micropapillary-ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components.

An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers.

Loss of heterozygosity at 2q37 in sporadic Wilms' tumor: putative role for miR-562.

The molecular underpinning of lobular histological growth pattern: a genome-wide transcriptomic analysis of invasive lobular carcinomas and grade- and molecular subtype-matched invasive ductal carcinomas of no special type.

Microglandular adenosis or microglandular adenoma? A molecular genetic analysis of a case associated with atypia and invasive carcinoma.

Complex landscapes of somatic rearrangement in human breast cancer genomes.

Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas.

FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.

Breast cancer molecular profiling with single sample predictors: a retrospective analysis.

Cortactin gene amplification and expression in breast cancer: a chromogenic in situ hybridisation and immunohistochemical study.

Genomic and immunohistochemical analysis of adenosquamous carcinoma of the breast.

DNA amplifications in breast cancer: genotypic-phenotypic correlations.

PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study.

Transcriptomic analysis of tubular carcinomas of the breast reveals similarities and differences with molecular subtype-matched ductal and lobular carcinomas.

BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells.

Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type.

Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer.

PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors.

β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation.

Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers.

Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas.

Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement.

Genomic profiling of mitochondrion-rich breast carcinoma: chromosomal changes may be relevant for mitochondria accumulation and tumour biology.

Next-generation sequencing applied to molecular diagnostics.

FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo.

Functional characterization of EMSY gene amplification in human cancers.

High-throughput detection of fusion genes in cancer using the Sequenom MassARRAY platform.

Molecular profiling reveals frequent gain of MYCN and anaplasia-specific loss of 4q and 14q in Wilms tumor.

Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma.

Non-existence of caveolin-1 gene mutations in human breast cancer.

Functional viability profiles of breast cancer.

Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers.

Immunophenotypic and genomic characterization of papillary carcinomas of the breast.

Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines.

Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer.

Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection.

APRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancer.

A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers.

Functional characterization of the 19q12 amplicon in grade III breast cancers.

Molecular evidence in support of the neoplastic and precursor nature of microglandular adenosis.

Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib.

Mutation profiling of adenoid cystic carcinomas from multiple anatomical sites identifies mutations in the RAS pathway, but no KIT mutations.

From integrative genomics to therapeutic targets.

Genomic profiling of histological special types of breast cancer.

Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.

Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast.

Integrative genomic and transcriptomic characterization of papillary carcinomas of the breast.

Unbiased analysis of potential targets of breast cancer susceptibility loci by Capture Hi-C.

Metaplastic breast carcinomas display genomic and transcriptomic heterogeneity [corrected]. .

SF3B1 mutations constitute a novel therapeutic target in breast cancer.

Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms.

Corrigendum: metastatic breast carcinomas display genomic and transcriptomic heterogeneity.

Breast cancer heterogeneity: parallel evolution or conscious uncoupling?

Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification.

Genomic landscape of adenoid cystic carcinoma of the breast.

An ecological measure of immune-cancer colocalization as a prognostic factor for breast cancer.

The status of epidermal growth factor receptor in borderline ovarian tumours.

Microenvironmental Heterogeneity Parallels Breast Cancer Progression: A Histology-Genomic Integration Analysis.

Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines.

Risk Stratification and Intrinsic Subtype Classification of Breast Cancer: a Multi-Parameter Test to Rule Them All?

Three-dimensional modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model.

Systematic analysis of tumour cell-extracellular matrix adhesion identifies independent prognostic factors in breast cancer.

Comparative proteomic assessment of matrisome enrichment methodologies.

Dual Targeting of PDGFRα and FGFR1 Displays Synergistic Efficacy in Malignant Rhabdoid Tumors.